Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Moxetumomab Pasudotox

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    AZ`s Luxomiti (Moxetumomab pasudotox tdfk) Receives Supp. Approval in US
    AZ`s Luxomiti (Moxetumomab pasudotox tdfk) Receives Supp. Approval in US

    21 Aug 2020

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761104

    FDA
    21 Aug 2020
    Share Share
    AZ's Lumoxiti (Moxetumomab Pasudotox TDFK) Receives Supplemental Approval in US
    AZ's Lumoxiti (Moxetumomab Pasudotox TDFK) Receives Supplemental Approval in US

    20 Aug 2020

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761104

    FDA
    20 Aug 2020
    Share Share
    EMA Accepts Regulatory Submission For Lumoxiti In Relapsed Or Refractory HCL
    EMA Accepts Regulatory Submission For Lumoxiti In Relapsed Or Refractory HCL

    02 Jan 2020

    // NASDAQ

    https://www.nasdaq.com/articles/ema-accepts-regulatory-submission-for-lumoxiti-in-relapsed-or-refractory-hcl-2020-01-02

    NASDAQ
    02 Jan 2020
    Share Share
    AstraZeneca's Calquence treads on Imbruvica's turf with second phase 3 CLL win
    AstraZeneca's Calquence treads on Imbruvica's turf with second phase 3 CLL win

    07 Jun 2019

    // Carly Helfand FIERCE PHARMA

    https://www.fiercepharma.com/pharma/astrazeneca-s-calquence-treads-imbruvica-s-turf-second-ph3-cll-win

    Carly Helfand FIERCE PHARMA
    07 Jun 2019
    Share Share
    AZ vet Jennifer Butler takes charge of Innate Pharma’s US biz; C4 raids NIBR
    AZ vet Jennifer Butler takes charge of Innate Pharma’s US biz; C4 raids NIBR

    16 Mar 2019

    // Amber Tong ENDPTS

    https://endpts.com/astrazeneca-vet-jennifer-butler-takes-charge-of-innate-pharmas-us-biz-c4-raids-nibr/

    Amber Tong ENDPTS
    16 Mar 2019
    Share Share
    Innate's hires Jennifer Butlers to commercialisation of leukaemia drug Lumoxiti
    Innate's hires Jennifer Butlers to commercialisation of leukaemia drug Lumoxiti

    13 Mar 2019

    // PHARMAFILE

    http://www.pharmafile.com/appointment/520394/innate-pharma-hires-jennifer-butlers-lead-commercialisation-leukaemia-drug-lumoxi

    PHARMAFILE
    13 Mar 2019
    Share Share